comparemela.com
Home
Live Updates
Ian De Boer - Breaking News
Pages:
Ian De Boer News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Will Kidney Disease Patients Finally Receive New Drug Class?
Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?
San francisco
United states
Donalda molony
Tazeenh jafar
Diana kwong
Drug administration
Kidney research institute
University of california
University of washington
Kidney disease
Improving global outcomes
Gross underuse
Medical school
Ian de boer
Chi yuan hsu
Choosing among dapa
FDA Panel Endorses Kidney Disease Drug for Serum Phosphorus Control
Advisors see need for alternatives, citing suboptimal efficacy and tolerance of approved options
United states
Julia lewis
Thomas cook
C noel bairey merz
Scott emerson
Los angeles
Christopher oconnor
Patrick nachman
Bairey merz
Sinai medical center
Renal drugs advisory committee on
Vanderbilt medical center
University of wisconsin
University of washington seattle
Vascular institute in falls church
University of washington
vimarsana © 2020. All Rights Reserved.